GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	TWD 23.00	-1.08%	81,414
06/08/26	TWD 23.25	+1.75%	130,448
05/08/26	TWD 22.85	+0.66%	140,826
04/08/26	TWD 22.70	0.00%	83,179
03/08/26	TWD 22.70	+2.02%	76,094

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 07/08/2026			5-day change	1st Jan Change
23.00 ^TWD	-1.08%		+3.37%	-10.68%

03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI

Market Cap	2.59B 80.14M 69.32M 64.73M 59.38M 112M 7.63B 113M 759M 298M 3.82B 301M 294M 12.64B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.37B 73.34M 63.43M 59.24M 54.34M 102M 6.98B 104M 695M 273M 3.5B 275M 269M 11.57B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
24/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
14/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
25/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
14/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI

1 day	-1.08%
1 week	+3.37%
Current month	+3.37%
1 month	-10.85%
3 months	+0.66%
6 months	-14.18%
Current year	-10.68%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	22.4	23.5
1 month	21.25	25.65
Current year	21.25	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-1.08%	+3.37%	+0.88%	-24.09%	80.14M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+1.80%	+5.82%	+76.22%	+100.97%	26.46B
Weighted average by Cap.	+2.54%	+6.09%	+104.22%	+140.73%

	2024	2025
Net sales	14.7M 455K 394K 368K 337K 634K 43.32M 645K 4.31M 1.69M 21.72M 1.71M 1.67M 71.79M	37.86M 1.17M 1.01M 947K 869K 1.63M 112M 1.66M 11.11M 4.36M 55.93M 4.4M 4.31M 185M
Net income	-230M -7.11M -6.15M -5.75M -5.27M -9.91M -677M -10.07M -67.41M -26.46M -339M -26.71M -26.13M -1.12B	-235M -7.28M -6.3M -5.88M -5.4M -10.15M -693M -10.31M -69.03M -27.09M -347M -27.35M -26.75M -1.15B
Net Debt	-442M -13.69M -11.84M -11.06M -10.14M -19.08M -1.3B -19.38M -130M -50.92M -653M -51.41M -50.28M -2.16B	-220M -6.8M -5.88M -5.5M -5.04M -9.48M -647M -9.63M -64.48M -25.31M -325M -25.55M -24.99M -1.07B